Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in two upcoming investor conferences. The Cowen 41^st Annual Health Care Conference is set for March 2, 2021, featuring a Microbiome panel discussion and 1x1 meetings. The Chardan 3^rd Annual Microbiome Medicines Summit will take place on March 8, 2021, where management will present a corporate overview at 2:30 p.m. ET and conduct 1x1 meetings. An audio webcast for the Chardan presentation will be available on Seres’ website. The company is at the forefront of microbiome therapeutics, with notable programs for recurrent C. difficile infection and ulcerative colitis.

Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in two upcoming investor conferences:

• Cowen 41^st Annual Health Care Conference on Tuesday, March 2, 2021. Management will participate in a Microbiome panel discussion as well as 1x1 meetings.
• Chardan 3^rd Annual Microbiome Medicines Summit on Monday, March 8, 2021. Management will present a corporate overview at 2:30 p.m. ET and participate in 1x1 meetings.

An audio webcast of the Chardan Summit presentation will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-401 in a Phase 1b study in patients with metastatic melanoma, SER-301 in a Phase 1b study in patients with ulcerative colitis, and SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005085/en/

FAQ

What conferences will Seres Therapeutics (MCRB) participate in March 2021?

Seres Therapeutics will participate in the Cowen 41st Annual Health Care Conference on March 2, 2021, and the Chardan 3rd Annual Microbiome Medicines Summit on March 8, 2021.

What is the significance of the SER-109 program for Seres Therapeutics (MCRB)?

The SER-109 program is significant as it achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has received Breakthrough Therapy and Orphan Drug designations from the FDA.

When can I access the audio webcast for Seres Therapeutics’ presentation at the Chardan Summit?

The audio webcast for Seres Therapeutics' presentation at the Chardan Summit will be available on their website approximately one hour after the event and archived for 21 days.

What therapeutic areas does Seres Therapeutics (MCRB) focus on?

Seres Therapeutics focuses on developing microbiome therapeutics for conditions such as recurrent C. difficile infection and ulcerative colitis.

What designations has Seres Therapeutics (MCRB) received for its SER-287 program?

The SER-287 program has received Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study for active mild-to-moderate ulcerative colitis.